SEPN
Septerna, Inc. NASDAQ Listed Oct 25, 2024$34.80
After hrs
$34.85
+0.00%
Mkt Cap $1.6B
52w Low $10.23
90.7% of range
52w High $37.32
50d MA $27.75
200d MA $24.77
P/E (TTM)
—
EV/EBITDA
—
P/B
4.0x
Debt/Equity
0.1x
ROE
-12.8%
P/FCF
14.0x
RSI (14)
76.60
ATR (14)
$1.96
Beta
3.50
50d MA
$27.75
200d MA
$24.77
Avg Volume
320.6K
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
250 East Grand Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.23 | -0.24 | -4.3% | 29.06 | +1.2% | -3.6% | -6.1% | +0.5% | -5.0% | +0.0% | — |
| Nov 10, 2025 | AMC | 0.19 | -0.09 | -147.4% | 18.10 | +1.3% | +6.3% | -0.1% | +0.1% | +20.9% | -7.0% | — |
| Aug 11, 2025 | AMC | -0.05 | -0.56 | -1020.0% | 11.49 | -4.3% | -2.5% | +4.4% | -0.1% | +0.3% | -1.1% | — |
| May 15, 2025 | AMC | -0.38 | -0.49 | -28.9% | 10.12 | +4.4% | -2.8% | +1.3% | -5.5% | -3.8% | +4.6% | — |
| Mar 27, 2025 | AMC | -0.69 | -0.64 | +7.2% | 6.29 | -5.7% | -3.0% | -5.1% | -13.3% | +9.4% | +5.6% | — |
| Nov 21, 2024 | AMC | -0.83 | -8.40 | -912.0% | 21.79 | -0.9% | +1.0% | +5.7% | +4.4% | +2.1% | +2.1% | — |
| Dec 31, 2023 | AMC | — | 2.05 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.56 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 | Guggenheim | Initiates | Buy | $52 | $30.47 | $30.86 | +1.3% | +11.7% | +5.6% | +0.2% | -2.4% | +1.8% |
| May 1 | Stifel | Initiates | Buy | $43 | $23.76 | $23.84 | +0.3% | -0.6% | +5.1% | -2.8% | +2.4% | -3.0% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.34 | $23.57 | +1.0% | +3.4% | +7.5% | -3.6% | +4.6% | +2.8% |
| Mar 24 | JP Morgan | Maintains | Overweight → Overweight | — | $23.78 | $23.77 | -0.0% | -1.4% | +3.3% | +2.2% | -3.5% | -2.4% |
| Mar 11 | Truist | Maintains | Buy → Buy | — | $28.02 | $27.45 | -2.0% | -6.1% | +0.5% | -5.0% | +0.0% | +0.1% |
| Mar 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $28.64 | $28.51 | -0.5% | -1.8% | +2.5% | -4.7% | +4.8% | +1.0% |
| Mar 2 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $29.02 | $28.11 | -3.1% | -1.3% | -1.8% | +2.5% | -4.7% | +4.8% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.02 | $28.11 | -3.1% | -1.3% | -1.8% | +2.5% | -4.7% | +4.8% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.07 | $26.37 | +1.2% | +3.7% | -2.5% | +1.2% | -3.4% | +0.8% |
| Nov 14 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $19.24 | $19.69 | +2.3% | +20.9% | -7.0% | +0.2% | +6.5% | +2.9% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.10 | $18.34 | +1.3% | +6.3% | -0.1% | +0.1% | +20.9% | -7.0% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $14.12 | $14.35 | +1.6% | +2.2% | +1.7% | +3.7% | -3.3% | -2.0% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.09 | $11.08 | -0.1% | +5.5% | +2.5% | -0.3% | +6.2% | -0.6% |
| May 16 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $10.12 | $10.57 | +4.4% | -2.8% | +1.3% | -5.5% | -3.8% | +4.6% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.12 | $10.57 | +4.4% | -2.8% | +1.3% | -5.5% | -3.8% | +4.6% |
| Mar 28 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.29 | $5.93 | -5.7% | -3.0% | -5.1% | -13.3% | +9.4% | +5.6% |
| Feb 18 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $12.96 | $4.17 | -67.8% | -47.0% | -19.2% | +6.1% | -1.5% | -1.2% |
| Feb 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.17 | $12.97 | -1.5% | -13.6% | -0.5% | +2.0% | +12.2% | -47.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Shaikhly Samira | Chief People Officer | Sell | 6,250 | $35.08 | $219K | 793 | +1.79% | — |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Sell | 2,889 | $29.66 | $86K | 793 | +2.68% | -1.74% |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Sell | 1,346 | $28.79 | $39K | 3,682 | +2.68% | -1.74% |
| Jun 1, 2026 | Shaikhly Samira | Chief People Officer | Sell | 1,700 | $27.78 | $47K | 5,028 | +2.68% | -1.74% |
| May 26, 2026 | Shaikhly Samira | Chief People Officer | Sell | 11,798 | $30.06 | $355K | 793 | -2.74% | +2.68% |
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
SEPN disclosed material information via press release in April 2026, potentially signaling news about RNA therapeutics pipeline progress or clinical results that could significantly impact the stock's valuation.
Apr 13
8-K
Septerna, Inc. -- 8-K Filing
Septerna reported positive Phase 1 results for SEP-631 in early 2026, advancing its GPCR-focused pipeline and demonstrating clinical progress for the clinical-stage biotech company.
Mar 9
8-K · 7.01
! Medium
Septerna, Inc. -- 8-K 7.01: Regulation FD Disclosure
Septerna will hold a conference call and webcast on March 2, 2026, at 8:00 a.m. to discuss company updates, providing investors an opportunity to hear management commentary directly.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Samsara Biocapital, Llc | 3,149,128 | $88M | — | Dec 2025 |
| 2 | Avoro Capital Advisors Llc | 1,337,500 | $32M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,196,962 | $29M | New | Mar 2026 |
| 4 | Adar1 Capital Management, Llc | 1,089,818 | $26M | New | Mar 2026 |
| 5 | Primecap Management Co/ca/ | 1,048,834 | $25M | Added | Mar 2026 |
| 6 | Janus Henderson Group Plc | 890,754 | $21M | New | Mar 2026 |
| 7 | Vr Adviser, Llc | 610,808 | $17M | — | Dec 2025 |
| 8 | Soleus Capital Management, L.p. | 275,000 | $7M | Reduced | Mar 2026 |
| 9 | Morgan Stanley | 207,970 | $6M | Added | Dec 2025 |
| 10 | Universal- Beteiligungs- Und Servicegesellschaft Mbh | 223,995 | $5M | Added | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 195,043 | $5M | New | Mar 2026 |
| 12 | Kalehua Capital Management Llc | 194,544 | $5M | — | Mar 2026 |
| 13 | Northern Trust Corp | 164,530 | $4M | Added | Mar 2026 |
| 14 | Millennium Management | 124,101 | $3M | Added | Mar 2026 |
| 15 | Ubs Group Ag | 116,979 | $3M | Added | Mar 2026 |
| 16 | Hussman Strategic Advisors, Inc. | 105,000 | $3M | New | Mar 2026 |
| 17 | Checkpoint Capital L.p. | 100,300 | $2M | New | Mar 2026 |
| 18 | Invesco Ltd. | 82,868 | $2M | Reduced | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 84,674 | $2M | Added | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 75,367 | $2M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.57B
Enterprise Value
$1.23B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.30x
P/B
4.03x
P/S
21.32x
P/FCF
14.04x
EV/EBITDA
—
Shares Out
44.3M
Financials (TTM)
Revenue
$72.3M
Net Income
-$36.0M
EBITDA
-$52.1M
Free Cash Flow
$109.7M
Op Cash Flow
$110.2M
EPS Basic
$-1.10
EPS Diluted
$-0.81
EPS Forward
$-1.64
Gross Margin
99.4%
Op Margin
-77.1%
Net Margin
-49.9%
Balance Sheet
Total Assets
$596.2M
Total Liab.
$214.3M
Total Equity
$381.9M
Cash
$391.1M
LT Debt
$21.4M
Book Value/Sh
$8.63
Debt/Equity
0.06x
Current Ratio
4.73
Quick Ratio
4.73
Returns & Growth
ROE
-12.8%
ROA
-8.2%
ROIC
-15.8%
Rev Growth YoY
+4174.5%
EPS Growth YoY
+84.9%
Price Returns
2W
+6.6%
1M
+27.1%
3M
+4.1%
6M
+4.1%
12M
+226.5%
Technicals
52W High
$37.32
52W Low
$10.23
50d MA
$27.75
200d MA
$24.77
RSI (14)
76.60
ATR (14)
$1.96
Beta
3.50
Avg Volume
321K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$39.00
High
$60.00
Low
$28.00
Median
$35.00
Data updated apr 27, 2026 12:45am
· Source: financialmodelingprep.com